Apollon Financial LLC Boosts Holdings in Iterum Therapeutics plc (NASDAQ:ITRM)

Apollon Financial LLC lifted its stake in shares of Iterum Therapeutics plc (NASDAQ:ITRM) by 11.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 250,250 shares of the company’s stock after acquiring an additional 25,500 shares during the quarter. Apollon Financial LLC owned approximately 0.91% of Iterum Therapeutics worth $443,000 at the end of the most recent reporting period.

Separately, XTX Topco Ltd purchased a new position in shares of Iterum Therapeutics in the 3rd quarter worth $36,000. 9.21% of the stock is currently owned by institutional investors.

Iterum Therapeutics Stock Performance

ITRM opened at $1.43 on Friday. The stock’s fifty day moving average is $1.81 and its two-hundred day moving average is $1.44. Iterum Therapeutics plc has a 52 week low of $0.81 and a 52 week high of $3.02.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.